Manufacturing of recombinant therapeutic proteins in microbial systems

  title={Manufacturing of recombinant therapeutic proteins in microbial systems},
  author={Klaus Graumann and A. Premstaller},
  journal={Biotechnology Journal},
  • Klaus Graumann, A. Premstaller
  • Published 2006
  • Biology, Medicine
  • Biotechnology Journal
  • Recombinant therapeutic proteins have gained enormous importance for clinical applications. The first recombinant products have been produced in E. coli more than 20 years ago. Although with the advent of antibody‐based therapeutics mammalian expression systems have experienced a major boost, microbial expression systems continue to be widely used in industry. Their intrinsic advantages, such as rapid growth, high yields and ease of manipulation, make them the premier choice for expression of… CONTINUE READING
    169 Citations

    Topics from this paper.

    Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements
    • 274
    • Highly Influenced
    Cellular engineering for therapeutic protein production: product quality, host modification, and process improvement
    • 48
    Therapeutic glycoprotein production in mammalian cells.
    • 115
    Environmental and recombinant microorganisms for biopharmaceuticals production
    • 1
    • Highly Influenced
    • PDF
    Active Protein Aggregates Produced in Escherichia coli
    • 51
    • PDF


    Recombinant antimicrobial peptides efficiently produced using novel cloning and purification processes
    • 14
    Advances in the production of human therapeutic proteins in yeasts and filamentous fungi
    • 377
    • PDF
    Recombinant protein expression for therapeutic applications.
    • 355
    Advances in Escherichia coli production of therapeutic proteins.
    • J. Swartz
    • Biology, Medicine
    • Current opinion in biotechnology
    • 2001
    • 409
    • PDF
    Preparative expression of secreted proteins in bacteria: status report and future prospects.
    • 188
    • PDF
    Bacillus subtilis as a tool for vaccine development: from antigen factories to delivery vectors.
    • 56
    • PDF